Digest Network Come funziona
Network
/
Società
AA
Non verificato

AAVantgarde

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaLegge/Diritto/FiscoMedicina Salute Benessere

11 comunicati stampa

Guarda tutti i comunicati
15/01/2026
Biotecnologia
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
08/01/2026
Biotecnologia
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotecnologia
Finanza
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
07/10/2025
Biotecnologia
AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
02/10/2025
Biotecnologia
Medicina Salute Benessere
Legge/Diritto/Fisco
Annunci Economici
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
05/09/2025
Biotecnologia
Medicina Salute Benessere
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
28/08/2025
Biotecnologia
Medicina Salute Benessere
AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
12/08/2025
Biotecnologia
Annunci Economici
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
15/07/2025
Biotecnologia
Medicina Salute Benessere
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0
12/05/2025
Biotecnologia
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
Fonte
AAVantgarde
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0